Drug Topics March 8, 2024
Lauren Biscaldi, MS, Managing Editor

Study results demonstrated the efficacy of semaglutide (Wegovy) in reducing cardiovascular risks in adults with overweight or obesity without diabetes.

Semaglutide (Wegovy) has earned FDA approval for a new indication: in addition to treating overweight and obesity in adults and children aged 12 years and older, Novo Nordisk’s injection can now be used to reduce the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease and either overweight or obesity.1,2

The FDA granted the glucagon-like peptide-1 (GLP-1) receptor agonist a priority review designation for this indication.

The agency’s decision comes after an analysis of data from the multicenter, multinational, double-blind, placebo-controlled, phase 3 SELECT clinical trial (NCT03574597). These data were presented in a late-breaking abstract at...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma / Biotech
Related Articles:
Insurer Denies Access To Drugs Granted Accelerated Approval By FDA
FDA Approves Third Tocilizumab Biosimilar
The Biden Administration’s Swan Song on Digital Health: Two FDA Guidances on Artificial Intelligence and FDA’s Defense of its Clinical Decision Support Guidance
FDA warns GLP-1 compounder over safety rules
GLP-1 drug approvals: A breakdown

Share This Article